News
Artificial intelligence, technology, science, health and education — reported daily, with the original source attached to every item.
4 stories
Two Independent Trials Report Responses in KRAS G12D Cancers, but Nature Medicine Editorial Urges Caution
Two Nature Medicine trials of oral and intravenous KRAS G12D inhibitors report response rates of 41% and 63.3% in advanced solid tumors and pancreatic cancer, but an accompanying editorial calls the results a start, not a settled breakthrough.
Single-Infusion In Vivo CAR T-Cell Therapy Eases Four Neurologic Autoimmune Diseases in Small NEJM Trial
A 16-patient trial published in NEJM on September 3, 2026 tested a single-infusion lentiviral vector that generates CD19 CAR T cells inside…
A Common Epilepsy Drug Is Linked to Longer Survival in an Almost Untreatable Childhood Brain Tumor
A retrospective Nature Medicine study (Sept. 17, 2026) led by Stanford Medicine finds children with diffuse midline glioma survived longer …
A Blood-Based Score Combining Ten microRNAs and CA19-9 Flags Early Pancreatic Cancer in a 1,785-Person Study
A prospective 1,785-person study published in Nature Medicine on September 16, 2026, found that PANXEON — a blood test combining ten microR…